Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis.
暂无分享,去创建一个
E. Montomoli | G. Mattiuzzo | R. Raqib | P. Calandro | R. Jeeninga | B. Hallis | S. Charlton | P. Sarker | Y. Bartsch | A. Roy | H. Buitendijk | R. Coluccio | José Vila-Belda | Livia Mazzini | A. Anantharaj | Pamela C. Proud | E. Molesti | Aymeric Fabié | A. Boccuto | V. Bernasconi | J. Singh | Philipa Levesque-Damphousse | Yann Le Duff | Matthew Hurley | Ilaria Razzano | Mustafizur Rahman | M. Jarju | Jane Mitchell | Mark Manak | Luc Gagnon | Steven Phay-Tran | Matthieu Daugan | S. Khan | Bethan Hussey | Daniel Knott | Guruprasad K Medigeshi | Neha Garg | Mohammad Mamun Alam | Marta Murreddu | Angela Balgobind | Rick Hofman | Silvia Grappi | Sandra Prior | Mark Page | Lauren M Schwartz | Ali Azizi | Vijay Zala | Ana Paula De Almeida | Helen Fassoulas | Tanvi Agrawal | Saskia Berndsen | Marina de Mooij | Coen Stalpers | Filippo Battistella | Danny Duijsings | Angela Holder | Edward Mee | Jennifer Padley | Nicola Rose | Trina Gorman | Hannah James | Jerome Carless
[1] N. Lurie,et al. Delivering Pandemic Vaccines in 100 Days - What Will It Take? , 2022, The New England journal of medicine.
[2] J. Knight,et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study , 2022, The Lancet Microbe.
[3] Melissa G. Pike,et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 , 2022, MMWR. Morbidity and mortality weekly report.
[4] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[5] G. Mattiuzzo,et al. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community , 2021, The Lancet Microbe.
[6] J. Tregoning,et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.
[7] Bofeng Li,et al. Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis , 2021, Frontiers in Molecular Biosciences.
[8] A. Telenti,et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern , 2021, Science.
[9] M. Wener,et al. Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity , 2021, Journal of clinical microbiology.
[10] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[11] C. Rice,et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.
[12] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[13] D. Altmann,et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.
[14] M. Carroll,et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays , 2021, Nature Protocols.
[15] W. Dowling,et al. Status Report on COVID-19 Vaccines Development , 2021, Current Infectious Disease Reports.
[16] A. Kumar,et al. Considerations for bioanalytical characterization and batch release of COVID-19 vaccines , 2021, NPJ vaccines.
[17] A. Fiore-Gartland,et al. Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.
[18] Y. Kreiss,et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.
[19] V. Gushchin,et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.
[20] Nguyen H. Tran,et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.
[21] V. Kulasingam,et al. Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation , 2021, Journal of Clinical Microbiology.
[22] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[23] A. Iafrate,et al. COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.
[24] A. Iafrate,et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients , 2020, Science Immunology.
[25] Yuquan Wei,et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.
[26] M. Chen,et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.
[27] Andrea Benedetti,et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis , 2020, BMJ.
[28] Radleigh G. Santos,et al. Improvement of IFNγ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis , 2014, Cells.